prikaz prve stranice dokumenta Minimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena
  Download
PDF 896.72 KB
master's thesis
Minimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena
Zagreb: University of Zagreb, School of Medicine, 2017. urn:nbn:hr:105:414465
Sorić, Ena
University of Zagreb
School of Medicine
Department of Internal Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Sorić, E. (2017). Minimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:414465

Sorić, Ena. "Minimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena." Master's thesis, University of Zagreb, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:105:414465

Sorić, Ena. "Minimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena." Master's thesis, University of Zagreb, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:105:414465

Sorić, E. (2017). 'Minimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena', Master's thesis, University of Zagreb, School of Medicine, accessed 07 November 2024, https://urn.nsk.hr/urn:nbn:hr:105:414465

Sorić E. Minimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2017 [cited 2024 November 07] Available at: https://urn.nsk.hr/urn:nbn:hr:105:414465

E. Sorić, "Minimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2017. Available at: https://urn.nsk.hr/urn:nbn:hr:105:414465

Metadata
TitleMinimalna ostatna bolest kronične mijeloične leukemije kroz mjerenje transkripta BCR-ABL onkogena
Title (english)Minimal residual disease of chronic myeloid leukemia through BCR-ABL fusion gene monitoring
AuthorEna Sorić
MentorRajko Kušec (mentor)
Committee memberVlatko Pejša (predsjednik povjerenstva)
Committee memberNikola Đaković (član povjerenstva)
Committee memberRajko Kušec (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Zagreb
Defense date and country2017-07-14, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Kronična mijeloična leukemija mijeloproliferativni je poremećaj obilježen translokacijom između 9. i 22. kromosoma zvanom Philadelphia (Ph) kromosom. Pri tome nastaje fuzijski gen BCR-ABL čiji je konačni učinak trajna aktivacija tirozin kinaze, čime se remeti niz staničnih funkcija. Kako bi se pratio tijek bolesti, analizirala minimalna ostatna bolest te procijenio odgovor na liječenje, pacijentima se kvantificira razina BCR-ABL transkripata te se izražava kao postotak na internacionalnoj skali. U našem istraživanju analizirano je 65 pacijenata dijagnosticiranih u KB Dubrava, Zagreb, u razdoblju između 1997. i 2016. godine, kojima je pomoću qRT-PCR mjerena razina BCR-ABL transkripata i ocijenjen odgovor na liječenje inhibitorima tirozin kinaze. MMR postignut je u 91,1% pacijenata, MR4 u 76,9% pacijenata, a nemjerljivost u 63,1% pacijenata. Fluktuacija za više od 0,5 log povezana je s kraćim vremenom do postizanja nemjerljivosti. Zaključno, mjerenje transkripata BCR-ABL onkogena adekvatna je metoda za praćenje minimalne ostatne bolesti kronične mijeloične leukemije.
Abstract (english)
Chronic myeloid leukemia is a myeloproliferative disorder characterized by translocation between chromosome 9 and 22 called Philadelphia (Ph) chromosome. This generates a fusion BCR-ABL gene whose ultimate effect is the continuous activation of tyrosine kinase, thereby disrupting cellular functions. To monitor the course of the disease, analyze the minimal residual disease, and evaluate the response to the treatment, the BCR-ABL transcript level is quantified and expressed as a percentage on an international scale (IS). In our study, 65 patients diagnosed in KB Dubrava, Zagreb in the period between 1997 and 2016 were analyzed by using qRT-PCR to measure levels of BCR-ABL transcripts and the response to the treatment of tyrosine kinase inhibitors was evaluated. MMR was achieved in 91.1% of patients, MR4 in 76.9% of patients, and undetecable disease in 63.1% of patients. The fluctuation of more than 0.5 logs is associated with a shorter time to reach undetectable disease. To conclude, measurement of transcripts of BCR-ABL oncogene is an adequate method for monitoring the minimal residual disease of chronic myeloid leukemia.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:414465
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-11-07 11:12:38